TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Meribel Pharma Höganäs AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
173,889
|
187,265
|
162,943 |
| Financial expenses |
4,553
|
8,563
|
8,160 |
| Earnings before taxes |
-40,187
|
-16,112
|
-23,130 |
| EBITDA |
-29,234
|
-2,060
|
-11,418 |
| Total assets |
184,821
|
178,291
|
120,121 |
| Current assets |
151,137
|
140,839
|
73,935 |
| Current liabilities |
47,756
|
159,051
|
112,190 |
| Equity capital |
137,065
|
19,240
|
7,931 |
| - share capital |
100
|
100
|
100 |
| Employees (average) |
89
|
91
|
103 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
74.2%
|
10.8%
|
6.6% |
| Turnover per employee |
1,954
|
2,058
|
1,582 |
| Profit as a percentage of turnover |
-23.1%
|
-8.6%
|
-14.2% |
| Return on assets (ROA) |
-19.3%
|
-4.2%
|
-12.5% |
| Current ratio |
316.5%
|
88.5%
|
65.9% |
| Return on equity (ROE) |
-29.3%
|
-83.7%
|
-291.6% |
| Change turnover |
-13,376
|
24,322
|
39,185 |
| Change turnover % |
-7%
|
15%
|
32% |
| Chg. No. of employees |
-2
|
-12
|
-3 |
| Chg. No. of employees % |
-2%
|
-12%
|
-3% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.